Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

pembrolizumab 602Cyclophosphamide 545Magnetic Resonance Spectroscopy 524Radiotherapy 513Specimen Handling 506Nivolumab 412Cisplatin 380Carboplatin 368Biopsy 306Blood Specimen Collection 302Radiosurgery 290Paclitaxel 280Surveys and Questionnaires 270Gemcitabine 270Standard of Care 267Drug Therapy 263Dexamethasone 263fludarabine 262Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 198Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 184Doxorubicin 179Etoposide 176atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carbamates × 1 year × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡